It is made available under a CC-BY 4.0 International license .

-	Title: Seroprevalence of chikungunya and o'nyong-nyong viruses in Senegal, West
2	Africa
3	
4	Authors: Prince Baffour Tonto ^{1,2} , Mouhamad Sy ³ , Ibrahima Mbaye Ndiaye ³ , Mariama
5	Toure ³ , Amy Gaye ³ , Mariama Aidara ³ , Amadou Moctar Mbaye ³ , Abdoulaye Kane Dia ^{3,4} ,
6	Mamadou Alpha Diallo ³ , Jules Francois Gomis ³ , Mamadou Samba Yade ³ , Younous
7	Diedhiou ³ , Baba Dieye ³ , Khadim Diongue ³ , Mame Cheikh Seck ³ , Aida S. Badiane ³ ,
8	Bobby Brooke Herrera ^{1,2*} , Daouda Ndiaye ³
9	
10	Affiliations:
11	1 Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA
12	2 Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases and
	2 Department of Medicine, Division of Allergy, Infindhology, and Infectious Diseases and
13	Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New
13 14	Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
13 14 15	 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA 3 International Research Training Center on Genomics and Health Surveillance
13 14 15 16	 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA International Research Training Center on Genomics and Health Surveillance (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal
13 14 15 16 17	 Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA International Research Training Center on Genomics and Health Surveillance (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal Laboratoire d'ecologie vectorielle et parasitaire
13 14 15 16 17 18	 2 Department of Medicine, Division of Allergy, mindulology, and mectious Diseases and Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA 3 International Research Training Center on Genomics and Health Surveillance (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal 4 Laboratoire d'ecologie vectorielle et parasitaire
13 14 15 16 17 18 19	 ² Department of Medicine, Division of Allergy, minutiloogy, and mectods Diseases and Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA ³ International Research Training Center on Genomics and Health Surveillance (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal ⁴ Laboratoire d'ecologie vectorielle et parasitaire *Corresponding Author: BBH, <u>bherrera@globalhealth.rutgers.edu</u>

20

- 21
- 22

It is made available under a CC-BY 4.0 International license .

23 Abstract

24 Background

Arthritogenic alphaviruses such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)
 viruses have shown capacity to cause widespread epidemics, with recurrent and sporadic

outbreaks occurring throughout sub-Saharan Africa.

28 Methods

27

We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing antibody titers against CHIKV and ONNV via enzyme-linked immunosorbent assay (ELISA) and microneutralization tests, respectively, and determined risk factors of CHIKV and ONNV exposure by binary logistic regression.

35 **Results**

36 The overall alphavirus seroprevalence based on an anti-CHIKV viral like particle (VLP) 37 IgG ELISA was 38.5%, with rates varying geographically: Kedougou (48.6%), Thies 38 (31.9%), and Sindia (14.9%). Neutralizing antibody titers revealed CHIKV and ONNV 39 seroprevalence rates of 7.4% and 9.8%, respectively, with significant variations by region 40 and age group. Cross-reactivity analysis showed that 82.9% of CHIKV cases exhibited a 41 neutralizing response to ONNV, while 71.7% of ONNV cases cross-neutralized CHIKV. 42 Residents of Thies had significantly higher odds of CHIKV infection (aOR, 3.147; 95% CI: 43 1.164-8.510) while ONNV infection was more likely in Kedougou (aOR, 3.888; 95% CI: 1.319-11.466). Furthermore, older age (> 40 years) was a significant risk factor both 44

It is made available under a CC-BY 4.0 International license .

45 CHIKV (aOR, 2.094; 95% CI: 0.846-5.185) and ONNV infection (aOR, 2.745; 95% CI:

1.212-6.216).

Conclusions

Our study confirms the co-circulation of CHIKV and ONNV in Senegal, highlighting their geographic and demographic distribution. These findings underscore the need for continued surveillance, alphavirus testing, and tailored public health strategies to mitigate their impact in Senegal.

- _ _

It is made available under a CC-BY 4.0 International license .

63 Introduction

64 Arboviruses transmitted by mosquitoes pose a growing global health threat, significantly impacting morbidity and mortality. Among these, chikungunya (CHIKV) and 65 66 o'nyong-nyong (ONNV) viruses are notable members of the alphavirus genus, recognized 67 for their substantial effects on human health (1, 2). CHIKV, first isolated in Tanzania in 1952, has caused major outbreaks across Africa, Asia, and the Americas (3-5). Its 68 69 transmission primarily involves Aedes mosquitoes, and its capacity for widespread 70 dissemination was highlighted by the 2004 epidemic that originated in Kenya and rapidly 71 extended to various regions, including the Indian Ocean islands and South and Southeast 72 Asia (1, 5-7). By 2011, CHIKV reached the Western Hemisphere, spreading through the 73 Caribbean and South America by 2014, resulting in hundreds of thousands of infections 74 (8-10).

75 ONNV, identified in Uganda in 1959, has caused significant epidemics primarily in 76 East and West Africa, with major outbreaks recorded in the 1950s and early 1990s (11-77 13). Transmitted by Anopheles mosquitoes, ONNV remains largely confined to the African 78 continent (6). The first major epidemic occurred from 1959 to 1962, affecting over 2 million 79 people across East and West Africa (14, 15). A subsequent outbreak from 1996 to 1997 80 primarily impacted Uganda, Kenva, and Tanzania, with infection rates ranging from 45-81 68% (14, 16). Despite its geographical confinement, ONNV has been detected in travelers 82 returning from endemic regions (17).

Clinically, infections with CHIKV and ONNV are generally self-limiting but can present a spectrum of symptoms including fever, arthralgia, rash, headache, and malaise (18, 19). CHIKV is particularly associated with persistent arthralgia in patients (20).

It is made available under a CC-BY 4.0 International license .

Although ONNV is endemic to Africa, comprehensive data on its morbidity and mortality are limited due to inadequate surveillance. The clinical features of alphavirus infections closely resemble those caused by other pathogens including *Plasmodium* (malaria) or *Salmonella* (typhoid fever) species, which are endemic in many West African countries (21-26). This symptom overlap complicates diagnosis and can lead to underreporting of CHIKV and ONNV, as their symptoms may be misattributed to other febrile illnesses.

92 In West Africa, including Senegal, autochthonous cases of CHIKV have been 93 reported since 1960, with periodic outbreaks continuing up to 2023 (27-31). Despite these 94 occurrences, current data on the seroprevalence of CHIKV and ONNV in Senegal 95 remains limited. This study aims to address this knowledge gap by investigating the 96 seroprevalence of CHIKV and ONNV in Senegal. Given the antigenic similarities between 97 these viruses, our approach focuses on using microneutralization assays to help 98 differentiate between them to provide a more in-depth understanding of their prevalence. 99 By enhancing our knowledge of the epidemiological landscape of CHIKV and ONNV in 100 Senegal, we hope to inform public health strategies and contribute valuable insights into 101 the broader context of arboviral transmission in West Africa.

102

103 Methods

Study Population and Ethics Statement

The samples included in our study were originally collected as part of malaria
and non-malarial surveillance among residents of Thies, Sindia, and Kedougou,
Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial
febrile illnesses, while samples from Kedougou were part of genomic surveillance of

It is made available under a CC-BY 4.0 International license .

109 malaria. Informed consent was obtained from all subjects and/or their legal guardians 110 for the initial sample collection as well as for its future use. All methods were performed 111 in accordance with the guidelines and regulations set forth by the Declaration of 112 Helsinki. The primary studies under which the samples and data were collected 113 received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol 114 numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding 115 data were banked and de-identified prior to the analyses. This study received and 116 exemption determination from the Rutgers Robert Wood Johnson Medical School IRB. 117

118 CHIKV viral like particle (VLP) ELISA

119 CHIKV VLPs (20 ng per well: Native Antigen) were coated onto Nunc Maxisorp 120 96-well plates (ThermoFisher) overnight, followed by blocking (1X PBST, 1% BSA; 121 ThermoFisher) for 1 hour, then washing (1X PBST three times) and incubation with 122 primary antibodies for 2 hours (serum at 1:400 dilution) at room temperature. The plates 123 were washed three times with 1X PBST and bound sera were reacted with secondary 124 antibodies (anti-human lgG conjugated with horseradish peroxidase [HRP]: 125 ThermoFisher), according to the manufacturer's instructions. The plates were washed three more times and allowed to develop with 1-Step TMB ELISA Substrate 126 127 (ThermoFisher), according to the manufacturer's instructions. The OD at 450 nm was 128 read with a reference wavelength of 650 nm using an ELISA reader (Diasource). We 129 interpreted the ELISA assay as follows: 1) sample absorbance / negative control 130 absorbance \leq 1.5, negative; 2) sample absorbance / negative control absorbance > 1.5, 131 positive.

It is made available under a CC-BY 4.0 International license .

132

133 Serum Microneutralization Assays

134 Microneutralization assays were performed to detect neutralizing antibodies 135 against CHIKV and ONNV in samples that were IgG positive for CHIKV VLP. Sera were 136 diluted in a two-fold series from 1:40 to 1:10,240 in PBS in a 96-well plate. For each 137 dilution, contact was performed with 100 plaque forming units (PFU) of CHIKV (BEI 138 Resources: NR-56523) or ONNV (BEI Resources: NR-51661) for one hour at 37°C in a 139 5% CO₂ incubator. The complexes were then added to Vero cells (ATCC) CCL-81, 1.3 x 140 10⁵ cells per well. After 3-4 days of incubation, the cytopathogenic effects were 141 investigated by 0.2% crystal violet (SigmaAldrich) staining. After staining for 2-4 hours, 142 the plates were washed with copious amounts of tap water. For negative controls, at least 143 3 alphavirus-naïve serum samples were used to incubate with CHIKV or ONNV prior to 144 pipetting onto the Vero cells per plate. For positive controls, 100 PFU of CHIKV or ONNV 145 without any contact with serum were placed on Vero cells in triplicate per plate.

146 The neutralizing titer was defined as the inverse of the highest dilution resulting in 147 an infectious reduction of 50%. A titer lower than 1:40 was considered as negative if 148 cytopathogenic effects were not observed. Samples were considered as positive if the 149 titer was ≥1:40, i.e., positive for ONNV if ONNV titers were at least two-fold higher than 150 CHIKV titers, and CHIKV positive if CHIKV titers were at least four-fold higher than ONNV 151 titers (32). The threshold was lower for ONNV than CHIKV because of the unique one-152 way cross-reactivity between CHIKV and ONNV, i.e., CHIKV antibodies are more likely 153 to cross-react with ONNV antigens than ONNV antibodies with CHIKV antigens (33). All other results were interpreted as equivocal. 20 Senegalese serum samples that were 154

It is made available under a CC-BY 4.0 International license .

previously determined to be alphavirus-naïve, were used to validate the assay. Each
assay used at least 4 alphavirus-naïve serum samples as negative controls.

157 Statistical Analysis

158 Categorical variables are represented as case counts and proportions, with 159 differences assessed using the Chi-square or Fisher exact test as appropriate. To 160 estimate the association between seroprevalence of alphavirus and demographics 161 factors, including age group, gender, city, a univariate binary logistic regression analysis 162 was performed. The adjusted odd ratios of the independent variables were computed by 163 adjusting for age and gender as confounding variables. Statistical analyses were 164 conducted using IBM SPSS statistics software version 28. The map of Senegal, heatmap, 165 and graph representing rates and percentages of CHIKV and ONNV neutralizing 166 antibodies were generated using R version 4.3.2 and Prism version 10.2.0.

167

168 **Results**

169 Characteristics of study subjects

A total of 470 samples collected from non-febrile subjects were included in the study. These samples were collected from three locations in Senegal: Sindia (n=94), Thies (n=94), and Kedougou (n=282). The samples from Sindia and Thies were malarianegative by rapid diagnostic testing, whereas the samples from Kedougou were from subjects with malaria. The study population were relatively young, with approximately 48% of them aged 20 years or younger, and consisted of fewer females, comprising 44.89%. (Table 1).

It is made available under a CC-BY 4.0 International license .

177 Prevalence of CHIKV and ONNV

We first employed an anti-CHIKV VLP IgG ELISA to screen 470 non-febrile serum samples. The CHIKV VLP antigen is specifically designed to detect IgG antibodies against CHIKV but can also recognize cross-reactive antibodies against related alphaviruses. Of the 470 samples tested, 181 were positive, resulting in an estimated alphavirus prevalence of 38.5%. Seroprevalence rates varied by location. Sindia had a rate of 14.9%, Thies had 31.9%, and Kedougou had 48.6% (Table 1).

184 Moreover, the microneutralization assay, regarded as the gold standard for 185 identifying prior exposure to a specific virus was utilized to differentiate exposure to 186 CHIKV and/or ONNV. Among the CHIKV IgG positive samples, 117 were available to 187 assess neutralizing antibodies against CHIKV and/or ONNV. The prevalence of 188 neutralizing antibodies against CHIKV and ONNV varied by location, gender, and age 189 group. The prevalence rates of CHIKV neutralizing antibodies were 6.4% in Sindia, 19.1% 190 in Thies, and 3.9% in Kedougou (Table 1). By gender, 7.0% for males and 8.0% for 191 females had CHIKV neutralizing antibodies (Table 2). Across age groups, the prevalence 192 was 7.6% in subjects aged ≤ 20 years, 5.3% in subjects aged 21 to 40 years, and 14.8% 193 in those over 40 years (Table 2). For ONNV, the neutralizing antibody prevalence rates 194 were 4.3% in Sindia, 4.3% in Thies, and 13.5% in Kedougou (Table 1). The prevalence 195 of ONNV neutralizing antibodies was 10.2% for males and 9.5% for females (Table 2). 196 Age-stratified prevalence showed a rate of 8.5 % in subjects aged ≤20 years, 8.0% in 197 subjects aged 21 to 40 years, and 20% in those over 40 years (Table 2).

Overall, 7.4% of the study subjects had neutralizing antibodies against CHIKV,
9.8% against ONNV, 5.1% were equivocal for both CHIKV and ONNV, and 2.6% were

negative, indicating prior exposure to other related alphaviruses (Table 1, Fig. 2A).
Moreover, of the subjects with CHIKV neutralizing antibodies, 82.9% had crossneutralizing antibodies against ONNV (Fig. 1B-C). However, subjects with ONNV
neutralizing antibodies, 71.7% had cross-neutralizing antibodies against CHIKV (Fig. 2BC).

205 Risk factors for CHIKV and ONNV infection

206 Univariate logistic regression, adjusted for age and gender, revealed that being a 207 resident of Thies (aOR, 2.384; 95% CI: 1.151-4.939) or Kedougou (aOR, 5.591; 95% CI: 208 3.001-10.418) were associated with increased odds of exposure to an alphavirus based 209 on IgG reactivity to CHIKV VLP, with the highest risk observed in Kedougou (S1 Table). 210 Modeling the presence of neutralizing antibodies to CHIKV against background factors 211 showed that subjects aged over 40 years had higher odds of CHIKV infection after 212 adjusting for age and gender (aOR, 2.094; 95% CI: 0.846-5.185), though this association 213 was marginally significant (Table 3). Additionally, the prevalence of CHIKV neutralizing 214 antibodies was higher in subjects aged over 40 years compared to the other age groups 215 (Fig 1A). Furthermore, subjects from Thies were more likely to be infected with CHIKV 216 (aOR, 3.147; 95% CI: 1.164-8.510) (Table 3), with a significantly higher prevalence of 217 CHIKV neutralizing antibodies in this city compared to Sindia and Kedougou (Fig 1B). 218 Residence of Kedougou was associated with significantly lower odds of contracting 219 CHIKV (aOR, 0.606; 95% CI: 0.217-1.692) (Table 3).

For ONNV, univariate analysis, adjusted for age and gender, revealed that subjects aged over 40 years (aOR, 2.745; 95% CI: 1.212-6.216) had significantly increased odds of infection (Table 3), with a significantly higher prevalence of ONVV

neutralizing antibodies in this age group compared to the other age groups (Fig 1A).
Subjects aged 21 to 40 (aOR, 0.682; 95% CI: 0.304-1.531) years were associated with
lower odds of ONNV infection (Table 3). Being a resident of Kedougou (aOR, 3.888; 95%
CI: 1.319-11.466) was associated with increase odds of ONNV infection (Table 3), with
significantly higher prevalence of ONVV neutralizing antibodies compared to the other
cities (Fig 2B). Residence from Thies was associated with lower odds of infection (aOR,
0.764; 95% CI: 0.179-3.256) (Table 3).

230

231 **Discussion**

232 In this study, we observed an overall alphavirus prevalence of 38.5% with notable 233 geographical variations. Virus-specific analysis revealed prevalence rates of 7.4% for 234 CHIKV exposure and 9.8% for ONNV, both exhibiting significant geographical and age-235 related variations. Cross-reactivity analysis showed that 82.9% of CHIKV cases exhibited 236 a neutralizing response to ONNV, while 71.7% of ONNV cases cross-neutralized CHIKV. 237 Older age emerged as a significant risk factor for ONNV exposure, and to a lesser extent 238 CHIKV. Additionally, ONNV exposure was significantly associated with residence in 239 Kedougou, while CHIKV exposure was strongly linked to residence in Thies. These 240 findings emphasize the continued transmission of alphaviruses in Senegal, specifically 241 CHIKV and ONNV, driven by geographic location as well as age-susceptibility.

The first documentation of a CHIKV human infection dates back to 1966 in Rufisque, a city near Dakar, as part of arbovirus surveillance programs led by the Institut Pasteur de Dakar. During this surveillance, CHIKV was detected in both mosquito vectors

It is made available under a CC-BY 4.0 International license .

and in human populations (29). Since then, numerous reports have documented CHIKV
circulation in the country, highlighting its endemicity and periodic re-emergence. A notable
example is the recent outbreak of CHIKV in Kedougou, which was attributed to the reemergence of an endemic strain (27).

249 To date, seroprevalence studies aimed at understanding CHIKV circulation in 250 Senegal have predominantly relied on detecting anti-CHIKV IgG antibodies using ELISA 251 (34, 35). However, this approach tends to overestimate CHIKV prevalence due to the 252 significant cross-reactivity between CHIKV and related alphaviruses, particularly ONNV. 253 This limitation highlights the need for more specific diagnostic methods, such as virus 254 neutralization assays or molecular techniques, to accurately discern CHIKV exposure and 255 better differentiate it from other co-circulating alphaviruses. Consequently, the use of a 256 microneutralization assay in this study allowed us to identify subjects with specific or 257 cross-reactive responses to either CHIKV or ONNV, providing a more accurate 258 assessment of their respective seroprevalence rates.

259 The prevalence rates for CHIKV and ONNV observed in our study differs from 260 those reported in similar studies in Senegal and other countries. For instance, a recent 261 study in Kedougou, involving inhabitants of 120 randomly selected villages, reported a 262 CHIKV prevalence of 54% (35), which is higher than both our overall observed rate and 263 the prevalence among the subjects from Kedougou in our study. An explanation for the 264 higher rate in this study is likely due to implementation of an anti-CHIKV IgG ELISA, which 265 measures cross-reactive alphavirus antibodies. In Nigeria, a systematic review 266 encompassing published literature spanning four decades reported a CHIKV prevalence 267 of 46.1% (36) based on neutralizing antibodies, a rate higher than that observed in the

It is made available under a CC-BY 4.0 International license .

present study. Additionally, our observed CHIKV prevalence rate is lower than the 56.5%
(37) reported among blood donors in Burkina Faso. Conversely, a study conducted in
Kenya reported CHIKV prevalence of 9.8% (38) among children from four communities
within the coastal and western regions, a rate comparable to our findings.

272 For ONNV, the prevalence rate observed in our study is lower than the 54.5% (37) 273 reported among blood donors in Burkina Faso, and the 28.4% (39) reported among HIV 274 patients in Madagascar. Importantly, both studies used anti-CHIKV IgG ELISAs to 275 measure antibody responses, which may have skewed the higher rates. Additionally, 276 modeling studies in Mali, using serological data estimated an ONNV prevalence of 30% 277 (33), also exceeding our observed rate. These discrepancies may be attributed to 278 differences in study population, sample size, methodological approaches, and ecological 279 or environment factors that influence virus transmission.

280 Our univariate logistic regression analysis identified older age as a risk factor for 281 both CHIKV and ONNV infection. We observed a higher prevalence of neutralizing 282 antibodies for both viruses in the older age group compared to their younger counterparts, 283 corroborating the notion that cumulative exposure over time contributes to higher 284 exposure rates. This demographic insight is crucial for developing targeted public health 285 strategies, especially for vaccine deployment and vector control initiatives. The 286 identification of older age as a risk factor for CHIKV infection is consistent with similar 287 findings from a study in Burkina Faso (37).

Furthermore, residents of Thies showed a three-fold increase in the likelihood of CHIKV infection compared to other regions, as evidenced by the higher prevalence of CHIKV neutralizing antibodies in Thies. Conversely, residents of Kedougou showed a

It is made available under a CC-BY 4.0 International license .

four-fold increase in the likelihood of ONNV infection, as evidenced by higher prevalence of ONNV neutralizing antibodies compared to the other regions. These regional differences may be attributed to distinct local vector ecologies or differences in human activities that increase exposure to virus-specific mosquito vectors. These hypotheses require further research.

296 We also observed that the prevalence of cross-neutralizing antibodies against 297 ONNV was higher among subjects with CHIKV neutralizing antibodies compared to those with ONNV neutralizing antibodies exhibiting cross-neutralization against CHIKV. These 298 299 findings corroborate a directional bias in immune cross-reactivity, where CHIKV exposure 300 might confer broader immunity, potentially impacting subsequent ONNV infection 301 dynamics (33). This asymmetric cross-reactivity could also be due to structural similarities 302 in the viral envelope proteins of CHIKV and ONNV, with CHIKV eliciting a broader 303 neutralizing response (33). This phenomenon is crucial for diagnostic tests, which may 304 need differentiation between past infections of these two viruses based on neutralizing 305 antibody profiles. Moreover, understanding the mechanisms behind this differential cross-306 reactivity could guide vaccine strategies where a vaccine against one virus might offer 307 partial protection against the other, hence optimizing the control measures for both 308 viruses in regions where they co-circulate.

One of the strengths of this study is our robust delineation of subjects previously exposed to CHIKV or ONNV in Senegal, achieved through the use of neutralization assays to minimize cross-reactivity. This methodological rigor makes our study the first to report the co-circulation of these antigenically related viruses in the country, providing valuable insights into their epidemiology and the public health risks they pose.

It is made available under a CC-BY 4.0 International license .

314 Despite its strengths, our study has several limitations. Of the 180 samples positive 315 for alphavirus IgG by ELISA, we were only able to perform neutralization assays on 117 316 due to sample availability. This limitation likely led to an underestimation of the true 317 prevalence of CHIKV and ONNV in our study populations. Additionally, while our use of 318 neutralization assays minimized cross-reactivity compared to the ELISA, a large 319 percentage of samples were considered equivocal, consistent with findings from other 320 studies. In contrast, other studies that rely solely on ELISA often classify these equivocal 321 results as positive, leading to potential overestimations of CHIKV prevalence (34, 35, 37). 322 Our approach provides a more conservative and potentially accurate estimate but 323 underscores the need for improved diagnostic tools to address the challenge of equivocal 324 results in alphavirus seroprevalence studies. Moreover, without concurrent clinical data, 325 we also cannot definitively link our serological findings to symptomatic disease cases, 326 underestimating the true burden of these infections. Additionally, the insights into antibody 327 cross-reactivity are essential for the interpretation of seroprevalence data in regions 328 endemic to both viruses, as they could lead to overestimations of immunity against one 329 virus due to past exposure to the other. This is particularly relevant in vaccine efficacy 330 trials and in the evaluation of natural immunity in the population.

331 Conclusions drawn from our research illustrate the persistent circulation of CHIKV 332 and ONNV in Senegal, necessitating sustained surveillance and public health 333 preparedness to mitigate the impact of these and other arboviruses. The findings also 334 emphasize the importance of ecological and demographic factors in shaping the 335 epidemiology of these diseases, highlighting the need for comprehensive arbovirus 336 control strategies that integrate vector management with community health initiatives.

It is made available under a CC-BY 4.0 International license .

- 337 Future studies should aim to incorporate entomological and clinical data to provide a more
- 338 holistic understanding of the transmission dynamics and to facilitate the development of
- targeted interventions, including vaccines and therapeutic measures.
- 340

341 Acknowledgements

- 342 We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson
- 343 Medical School, and the Child Health Institute of New Jersey.
- 344

345 **Conflicts of Interest**

- 346 BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops
- 347 diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.
- 348

349 Author Contributions

- 350 Conceptualization: BBH
- 351 Data curation: PBT, MS, IMN, MT, AG, MA, BBH, DN
- 352 Formal analysis: PBT, MS, IMN, MT, AG, MA, BBH, DN
- 353 Funding acquisition: BBH, DN
- 354 Investigation: PBT, MS, IMN, MT, AG, MA, BBH, DN
- 355 Methodology: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- 356 MCS, ASB, BBH, DN
- 357 Project administration: BBH, DN

It is made available under a CC-BY 4.0 International license .

- 358 Resources: BBH, DN
- 359 Software: PBT, MS, BBH
- 360 Supervision: BBH, MS, DN
- 361 Validation: PBT, MS, IMN, MT, AG, MA, BBH, DN
- 362 Visualization: PBT, MS, IMN, MT, AG, MA, BBH, DN
- 363 Writing original draft: PBT, BBH
- Writing review & editing: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY,
- 365 YD, BD, KD, MCS, ASB, BBH, DN
- 366

367 **References**

1. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al.

369 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2:

370 Epidemiological distribution of o'nyong-nyong virus. Antiviral Res. 2019;172:104611.

2. Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, et al. Arthritogenic

372 alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet

373 Infect Dis. 2021;21(5):e123-e33.

374 3. Renault P, Balleydier E, D'Ortenzio E, Baville M, Filleul L. Epidemiology of

375 Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal

- 376 Infect. 2012;42(3):93-101.
- 4. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus:
- 378 mapping the 64-year history. Int J Infect Dis. 2017;58:69-76.
- 379 5. Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and
- 380 Its Spread to New Regions in 2013-2014. J Infect Dis. 2016;214(suppl 5):S436-S40.

It is made available under a CC-BY 4.0 International license .

381 6. Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, et al.

382 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5:

383 Entomological aspects. Antiviral Res. 2020;174:104670.

384 7. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.

385 Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,

386 October 2004. Am J Trop Med Hyg. 2008;78(2):333-7.

387 8. Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious

388 Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas -

389 Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep.

390 2014;63(22):500-1.

391 9. Manzoor KN, Javed F, Ejaz M, Ali M, Mujaddadi N, Khan AA, et al. The global

392 emergence of Chikungunya infection: An integrated view. Rev Med Virol.

393 2022;32(3):e2287.

Teixeira MG, Andrade AM, Costa Mda C, Castro JN, Oliveira FL, Goes CS, et al.
East/Central/South African genotype chikungunya virus, Brazil, 2014. Emerg Infect Dis.
2015;21(5):906-7.

39711.Corbet PS, Williams MC, Gillett JD. O'Nyong-Nyong fever: an epidemic virus

398 disease in East Africa. IV. Vector studies at epidemic sites. Trans R Soc Trop Med Hyg.

399 1961;55:463-80.

400 12. Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-Nyong Fever: An

401 Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes.

402 Trans R Soc Trop Med Hyg. 1965;59:300-6.

It is made available under a CC-BY 4.0 International license .

403 13. Lanciotti RS, Ludwig ML, Rwaguma EB, Lutwama JJ, Kram TM, Karabatsos N,

404 et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence:

- 405 genetic characterization of the virus. Virology. 1998;252(1):258-68.
- 406 14. Rezza G, Chen R, Weaver SC. O'nyong-nyong fever: a neglected mosquito-
- 407 borne viral disease. Pathog Glob Health. 2017;111(6):271-5.
- 408 15. Williams MC, Woodall JP, Gillett JD. O'nyong-Nyong Fever: An Epidemic Virus
- 409 Diesease in East Africa. Vii. Virus Isolations from Man and Serological Studies up to
- 410 July 1961. Trans R Soc Trop Med Hyg. 1965;59:186-97.

411 16. Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba

412 R, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and

413 validation of a clinical case definition for surveillance purposes. Clin Infect Dis.

414 1999;29(5):1243-50.

415 17. Tappe D, Kapaun A, Emmerich P, Campos Rde M, Cadar D, Gunther S, et al.

416 O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. Emerg

- 417 Infect Dis. 2014;20(10):1766-7.
- 418 18. Johnson BK. O'nyong-nyong virus disease. Arboviruses: CRC Press; 2019. p.419 217-24.

420 19. Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur J Intern Med.

421 **2012;23(4):325-9**.

422 20. Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.

423 Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal

424 study. PLoS neglected tropical diseases. 2013;7(3):e2137.

It is made available under a CC-BY 4.0 International license .

425	21.	Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, et al. A			
426	multicountry molecular analysis of Salmonella enterica serovar Typhi with reduced				
427	susceptibility to ciprofloxacin in sub-Saharan Africa. Clinical Infectious Diseases.				
428	2016;6	62(suppl_1):S42-S6.			
429	22.	Badiane AS, Ngom B, Ndiaye T, Cunningham D, Campbell J, Gaye A, et al.			
430	Evidence of Plasmodium vivax circulation in western and eastern regions of Senegal:				
431	implications for malaria control. Malaria Journal. 2024;23(1):149.				
432	23.	Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An			
433	epider	niological study to assess Plasmodium falciparum parasite prevalence and			
434	malari	a control measures in Burkina Faso and Senegal. Malaria journal. 2017;16:1-12.			
435	24.	Diallo M, Diongue K, Diagne G, Seck M, Ndiaye M, Dièye B, et al. Plasmodium			
436	ovale	wallikeri and Plasmodium ovale curtisi Malaria in Senegal in 2016. Bulletin de la			
437	Sociét	é de pathologie exotique. 2017;110:286-90.			
438	25.	Dromigny J-A, Perrier-Gros-Claude J-D. Antimicrobial resistance of Salmonella			
439	enterio	ca serotype Typhi in Dakar, Senegal. Clinical infectious diseases. 2003;37(3):465-			
440	6.				
441	26.	Harrois D, Breurec S, Seck A, Delauné A, Le Hello S, de La Gandara MP, et al.			
442	Prevalence and characterization of extended-spectrum β -lactamase-producing clinical				
443	Salmo	nella enterica isolates in Dakar, Senegal, from 1999 to 2009. Clinical			
444	Microb	piology and Infection. 2014;20(2):O109-O16.			
445	27.	Dieng I, Sadio BD, Gaye A, Sagne SN, Ndione MHD, Kane M, et al. Genomic			
446	charac	cterization of a reemerging Chikungunya outbreak in Kedougou, Southeastern			

447 Senegal, 2023. Emerg Microbes Infect. 2024;13(1):2373308.

It is made available under a CC-BY 4.0 International license .

448 28. Pistone T, Ezzedine K, Boisvert M, Receveur MC, Schuffenecker I, Zeller H, et

449 al. Cluster of chikungunya virus infection in travelers returning from Senegal, 2006. J

450 Travel Med. 2009;16(4):286-8.

451 29. Roche S, Robin Y. [Human infections by Chikungunya virus in Rufisque

452 (Senegal), October-November, 1966]. Bull Soc Med Afr Noire Lang Fr. 1967;12(3):490-

453 **6**.

30. Saluzzo J, Cornet M, Digoutte J. Outbreak of a Chikungunya virus epidemic in
western Senegal in 1982. Dakar medical. 1983;28(3):497-500.

456 31. Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak

457 in Kedougou, Southeastern Senegal in 2009-2010. Open Forum Infect Dis.

458 2018;5(1):ofx259.

459 32. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al.

460 High rates of o'nyong nyong and Chikungunya virus transmission in coastal Kenya.

461 PLoS Negl Trop Dis. 2015;9(2):e0003436.

462 33. Hoze N, Diarra I, Sangare AK, Pastorino B, Pezzi L, Kouriba B, et al. Model-

463 based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a

serological cross-reactivity context. Nat Commun. 2021;12(1):6735.

465 34. de Souza WM, Gaye A, Ndiaye EH, Morgan AL, Sylla EHD, Sy FA, et al.

466 Serosurvey of Chikungunya Virus in Old World Fruit Bats, Senegal, 2020-2022. Emerg

467 Infect Dis. 2024;30(7):1490-2.

468 35. Sow A, Nikolay B, Faye O, Cauchemez S, Cano J, Diallo M, et al. Changes in the

469 Transmission Dynamic of Chikungunya Virus in Southeastern Senegal. Viruses.

470 2020;12(2).

It is made available under a CC-BY 4.0 International license .

471	36.	Abdullahi IN	Akande AO	Muhammed Y	Rogo I D	Oderinde BS, Prevalence
T/I	00.					

- 472 Pattern of Chikungunya Virus Infection in Nigeria: A Four Decade Systematic Review
- 473 and Meta-analysis. Pathog Glob Health. 2020;114(3):111-6.
- 474 37. Tinto B, Bicaba B, Kagoné TS, Kayiwa J, Rabe I, Merle CSC, et al. Co-circulation
- 475 of two Alphaviruses in Burkina Faso: Chikungunya and O'nyong nyong viruses. PLoS
- 476 Negl Trop Dis. 2024;18(6):e0011712.
- 477 38. Khan A, Bisanzio D, Mutuku F, Ndenga B, Grossi-Soyster EN, Jembe Z, et al.
- 478 Spatiotemporal overlapping of dengue, chikungunya, and malaria infections in children
- 479 in Kenya. BMC Infect Dis. 2023;23(1):183.
- 480 39. Rakotomalala FA, Bouillin J, Randriarimanana SD, Thaurignac G, Maharavo L,
- 481 Raberahona M, et al. High Seroprevalence of IgG Antibodies to Multiple Arboviruses in

482 People Living with HIV (PLWHIV) in Madagascar. Viruses. 2023;15(11).

483

484

- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492

т*)*2

It is made available under a CC-BY 4.0 International license .

Tables

- 496 Table 1. Baseline characteristics and chikungunya virus (CHIKV) and o'nyong-
- 497 nyong virus (ONNV) serology

	Sindia (n=94)	Thies (n=94)	Kedougou (n=282)	Total (n=470)	
Demographics		· · · ·		ŝ k	
Year(s) samples collected	2018	2018	2022-2023		
Age group, n (%)					
≤ 20 years	40 (42.6)	48 (41.1)	136 (48.2)	224 (47.7)	
21-40 years	42 (44.7)	23 (24.4)	123 (43.6)	188 (40.0)	
> 40 years	11 (11.7)	23 (24.4)	21 (7.5)	55 (11.7)	
Unreported	1 (1.0)	_	2 (0.7)	3 (0.6)	
Female gender, n (%)	39 (41.5)	51 (54.3)	121 (42.9)	211 (44.9)	
History of malaria infection, n (%)	0 (0)	0 (0)	282 (100)	282 (60)	
Serology	Serology				
CHIKV VLP IgG+, n (%)	14 (14.9)	30 (31.9)	137 (48.6)	181 (38.5)	
NT50, n (%)					
CHIKV	6 (6.4)	18 (19.1)	11 (3.9)	35 (7.4)	
ONNV	4 (4.3)	4 (4.3)	38 (13.5)	46 (9.8)	
Equivocal	4 (4.3)	5 (5.3)	15 (5.3)	24 (5.1)	
Negative	0 (0.0)	0 (0.0)	12 (4.3)	12 (2.6)	

504 Table 2. Baseline characteristics of NT50-confirmed chikungunya virus (CHIKV)

505 and o'nyong-nyong virus (ONNV) subjects

	Total n= 470	CHIKV NT50- confirmed subjects n=35	ONNV NT50- confirmed subjects n=46
Age group, n (%	ó)		
≤ 20 years	224 (47.7)	17 (7.6)	19 (8.5)
21-40 years	188 (40.0)	10 (5.3)	15 (8.0)
> 40 years	55 (11.7)	8 (14.8)	11 (20.0)
Unreported	3 (0.6)	0 (0.0)	1 (33.3)
Gender, n (%)			
Male	256 (54.5)	18 (7.0)	26 (10.2)
Female	211 (44.9)	17 (8.0)	20 (9.5)
Unreported	3 (0.6)	0 (0.0)	0 (0.0)
City, n (%)			
Sindia	94 (20.0)	6 (6.4)	4 (4.3)
Thies	94 (20.0)	18 (19.1)	4 (4.3)
Kedougou	282 (60.0)	11 (3.9)	38 (13.5)
History of malaria infection, n (%)	282 (60)	11 (3.9)	38 (13.5)

516 Table 3. Risk factors for chikungunya virus (CHIKV) and o'nyong-nyong virus

517 (ONNV) infections in Senegal

Univariate binary logistic regression							
Predictor	OR (95% CI)	p value	aOR (95%	CI)	p value		
CHIKV NT50-confirmed subjects							
Age group							
≤ 20 years	Reference	0.077	Reference 0.682	(0.304-	0.082		
21-40 years	0.687 (0.307-1.539)		1.531) 2.094	(0.846-			
> 40 years	2.128 (0.866-5.228)		5.185)	•			
Gender							
Male	Reference		Reference 1.100	(0.546-			
Female	1.153 (0.579-2.297)	0.686	2.213)	•	0.79		
City							
Sindia	Reference	<0.001	Reference 3.147	(1.164-	<0.001		
Thies	3.474 (1.312-9.196)		8.510) 0.606	(0.217-			
Kedougou	0.595 (0.214-1.657)		1.692)	Υ,			
	ONNV NT50-cor	nfirmed sub	jects				
Age group							
≤ 20 years	Reference	0.027	Reference 0.948	(0.467-	0.026		
21-40 years	0.936 (0.462-1.896)		1.924) 2.745	(1 212-			
> 40 years	2.697 (1.199-6.068)		6.216)	(1.212			
Gender							
Male	Reference		Reference	(0.470			
Female	0.926 (0.501-1.711)	0.807	0.897 1.683)	(0.478-	0.736		
City							
Sindia	Reference	0.008	Reference 0.764	(0.179-	0.002		
Thies	1.000 (0.243-4.122)		3.256) 3.888	(1.319-			
Kedougou	3.504 (1.216-10.096)		11.466)	(

⁵¹⁸ OR- Crude odd ratio; aOR- adjusted odd ratio for gender and age

It is made available under a CC-BY 4.0 International license .

520 Figures



522 Fig 1. Comparison of the prevalence of neutralizing antibodies to CHIKV and ONNV

by age group, city, and gender. Differences between (A) age, (B) city, and (C) gender 524 were assessed using the Chi-square test or Fisher's exact test, as appropriate. P-values 525 less than 0.05 were considered to be statistically significant, while values less than 0.1 526 were considered to be marginally significant.

It is made available under a CC-BY 4.0 International license .



539 Fig. 2. Antibody neutralization against chikungunya (CHIKV) and o'nyong-nyong 540 (ONNV) viruses in Senegal. (A) Map depicts locations in Senegal (Sindia, Thies, and 541 Kedougou) where samples were collected from non-febrile subjects. For each location, 542 bar charts represent the neutralizing antibody prevalence against CHIKV (C) or ONNV 543 (C), or equivocal (E) and negative (N) results. Prevalence values are listed above each 544 bar. (B) CHIKV virus-like particle IgG-positive samples (n=117) were tested for 545 neutralizing antibodies against CHIKV and ONNV. Colors depict the 50% neutralizing 546 antibody titers (NT50), each row represents one individual, and each column is the titer 547 to CHIKV or ONNV. (C) The percentage of NT50-confirmed CHIKV or ONNV subjects 548 with cross-neutralizing antibodies to the heterologous virus.